Skip to main content
SpringerLink
Log in

Les biomarqueurs émergents dans le cancer bronchique non à petites cellules

Emerging biomarkers in non-small cell lung cancer

  • Mise au Point / Update
  • Published:
Oncologie

Abstract

Since 2011, french molecular genetic platforms are able to routinely test, in addition to EGFR activating mutations and K-RAS mutations, five other biomarkers in patients with metastatic non-small cell lung cancer: EGFR resistance mutations, HER2 mutations, B-RAF mutations, PI3KCA mutations and EML4-ALK translocation. The aim of this article is to describe the potential impact of these biomarkers on therapeutic management.

Résumé

Depuis 2011, les plateformes françaises de génétique moléculaire peuvent tester en routine, en plus des mutations activatrices de l’EGFR et des mutations de K-RAS, cinq autres biomarqueurs chez les patients souffrant de cancer bronchique non à petites cellules (CBNPC) métastatique: les mutations de résistance de l’EGFR, les mutations de HER2, les mutations de B-RAF, les mutations de PI3KCA et la translocation EML4-ALK. L’objectif de cet article est de décrire l’impact potentiel de ces biomarqueurs sur la prise en charge thérapeutique.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. Camidge DR, Bang Y, Kwak EL, et al. (2011) Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 29: abstract 2501

  2. Cappuzzo F, Bemis L, Varella-Garcia M (2006) HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 354: 2619–2621

    Article  PubMed  CAS  Google Scholar 

  3. Chapman PB, Hauschild A, Robert C, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516

    Article  PubMed  CAS  Google Scholar 

  4. Crino L, Kim D, Riely GJ, et al. (2011) Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 29; abstract 7514

  5. De Greve JLP, Teugels E, De Mey J, et al. (2009) Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu. J Thor Oncol 4: S307 (abstract)

    Google Scholar 

  6. Kelly RJ, Carter C, Giaccone G (2010) Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small cell lung cancer using PF-00299804 and trastuzumab. J Clin Oncol 28: e507–e510

    Article  PubMed  CAS  Google Scholar 

  7. Kwak EL, Bang YJ, Camidge DR, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693–1703

    Article  PubMed  CAS  Google Scholar 

  8. Miller VA, Hirsh V, Cadranel J, et al. (2010) Phase IIB/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1–2 lines chemotherapy and erlotinib or gefitinib (LUX-Lung 1). 35th ESMO Congress: abstract LBA1

  9. Mok T, Spigel DR, Park K, et al. (2010) Efficacy and safety of PF299804 as first-line treatment (TX) of patients (PTS) with advanced (ADV) NSCLC selected for activating mutation (MU) of epidermal growth factor receptor (EGFR). 35th ESMO Congress: abstract LBA18

  10. Paik PK, Arcila ME, Fara M, et al. (2011) Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29: 2046–2051

    Article  PubMed  Google Scholar 

  11. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10: 760–774

    Article  PubMed  CAS  Google Scholar 

  12. Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175–180

    Article  PubMed  CAS  Google Scholar 

  13. Ramalingam SS, Boyer MJ, Park K, et al. (2010) Randomized phase 2 study of PF299804, an irreversible human epidermal growth factor receptor (EGFR) inhibitor, versus (V) erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) after chemotherapy (CT) failure: quantitative and qualitative benefits. 35th ESMO Congress: abstract 365PD

  14. Sequist LV, Waltman BA, Dias-Santagata D, et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26

    Article  PubMed  Google Scholar 

  15. Soda M, Choi YL, Enomoto M, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561–566

    Article  PubMed  CAS  Google Scholar 

  16. Yang C, Shih J, Su W, et al. (2010) A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-Lung 2). 35th ESMO Congress: abstract 367PD

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie multidisciplinaire & innovations thérapeutiques, Inserm UMR 911, hôpital Nord, Assistance publique Hôpitaux de Marseille, Aix-Marseille Univ, chemin des Bourrely, F-13915, Marseille cedex 20, France

    L. Greillier

Authors
  1. L. Greillier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Greillier.

About this article

Cite this article

Greillier, L. Les biomarqueurs émergents dans le cancer bronchique non à petites cellules. Oncologie 14, 316–319 (2012). https://doi.org/10.1007/s10269-012-2159-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-012-2159-4

Keywords

Mots clés

Search

Navigation